CSPC Pharmaceutical Group Limited - Asset Resilience Ratio

Latest as of December 2025: 5.94%

CSPC Pharmaceutical Group Limited (CVG) has an Asset Resilience Ratio of 5.94% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

€2.78 Billion
≈ $3.25 Billion USD Cash + Short-term Investments

Total Assets

€46.70 Billion
≈ $54.59 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how CSPC Pharmaceutical Group Limited's Asset Resilience Ratio has changed over time. Check CVG strategic asset allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down CSPC Pharmaceutical Group Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CSPC Pharmaceutical Group Limited (CVG) total market value.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €2.78 Billion 5.94%
Total Liquid Assets €2.78 Billion 5.94%

Asset Resilience Insights

  • Limited Liquidity: CSPC Pharmaceutical Group Limited maintains only 5.94% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

CSPC Pharmaceutical Group Limited Industry Peers by Asset Resilience Ratio

Compare CSPC Pharmaceutical Group Limited's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
AstraZeneca PLC
NYSE:AZN
Drug Manufacturers - General 0.10%
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
Drug Manufacturers - General 7.83%
AstraZeneca PLC
F:ZEGA
Drug Manufacturers - General 0.03%
Firebrick Pharma Ltd
AU:FRE
Drug Manufacturers - General 0.29%
Eli Lilly and Company
SA:LILY34
Drug Manufacturers - General 8.63%
Pfizer Inc
SA:PFIZ34
Drug Manufacturers - General 5.48%
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436
Drug Manufacturers - General 17.40%
Sichuan Kelun Pharmaceutical Co Ltd
SHE:002422
Drug Manufacturers - General 4.41%

Annual Asset Resilience Ratio for CSPC Pharmaceutical Group Limited (2016–2025)

The table below shows the annual Asset Resilience Ratio data for CSPC Pharmaceutical Group Limited.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 5.94% €2.78 Billion
≈ $3.25 Billion
€46.70 Billion
≈ $54.59 Billion
+2.63pp
2024-12-31 3.32% €1.47 Billion
≈ $1.72 Billion
€44.39 Billion
≈ $51.90 Billion
+0.99pp
2023-12-31 2.33% €1.08 Billion
≈ $1.26 Billion
€46.28 Billion
≈ $54.11 Billion
-6.23pp
2022-12-31 8.56% €3.57 Billion
≈ $4.18 Billion
€41.77 Billion
≈ $48.83 Billion
+4.40pp
2021-12-31 4.15% €1.44 Billion
≈ $1.69 Billion
€34.74 Billion
≈ $40.62 Billion
-0.95pp
2020-12-31 5.11% €1.54 Billion
≈ $1.79 Billion
€30.07 Billion
≈ $35.16 Billion
+5.10pp
2019-12-31 0.00% €536.00K
≈ $626.64K
€26.32 Billion
≈ $30.77 Billion
+0.00pp
2018-12-31 0.00% €441.76K
≈ $516.47K
€23.17 Billion
≈ $27.09 Billion
0.00pp
2017-12-31 0.00% €611.66K
≈ $715.10K
€18.00 Billion
≈ $21.05 Billion
0.00pp
2016-12-31 0.00% €466.51K
≈ $545.39K
€13.22 Billion
≈ $15.45 Billion
--
pp = percentage points

About CSPC Pharmaceutical Group Limited

F:CVG Germany Drug Manufacturers - General
Market Cap
$12.41 Billion
€10.61 Billion EUR
Market Cap Rank
#2215 Global
#462 in Germany
Share Price
€0.93
Change (1 day)
+0.31%
52-Week Range
€0.73 - €1.25
All Time High
€1.25
About

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining cap… Read more